Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 tralokinumab + topical corticosteroids in pediatric atopic dermatitis
2023-503630-44-00Phase 3Authorised
- Sponsor
- LEO Pharma
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of tralokinumab in atopic dermatitis (AD) (3 arms), sponsored by LEO Pharma. Primary endpoints: Investigator’s Global Assessment (IGA) 0/1 at Week 16 and EASI75 at Week 16. Planned start Nov 2024; status: authorised.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-503630-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503630-44-00.